Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
March 17, 2025 07:30 ET
|
Aptose Biosciences, Inc.
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
February 20, 2025 07:32 ET
|
Aptose Biosciences, Inc.
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
Aptose Announces Reverse Share Split
February 18, 2025 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Reverse Share Split
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
February 13, 2025 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Enters into $25 Million Committed Equity Facility and
Establishes New At-The-Market Facility
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
February 12, 2025 07:00 ET
|
Aptose Biosciences, Inc.
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses
in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
January 09, 2025 16:00 ET
|
Aptose Biosciences, Inc.
Aptose Announces First AML Patients Dosed with
Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Announces Positive Decision by Nasdaq Hearings Panel
December 19, 2024 16:05 ET
|
Aptose Biosciences, Inc.
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
December 12, 2024 10:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
December 09, 2024 12:00 ET
|
Aptose Biosciences, Inc.
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
December 03, 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations